Explore how private sector initiatives are supporting community oncology practices in offering clinical trials, addressing ...

Discover how NCOA6 loss is associated with aggressive prostate cancer and EGFR overexpression, highlighting potential ...

Learn about the promising results of triplet therapy in early bladder cancer treatment, offering new hope for patients.

The phase 3 DeLLphi-305 trial showed tarlatamab plus durvalumab significantly improved overall and progression-free survival ...

The FDA granted fast track designation to investigational therapies across a range of cancer types, including lung, prostate, gastrointestinal, and urothelial cancers. Here are the highlights.

Sacituzumab govitecan extends survival in advanced endometrial cancer post chemotherapy and immunotherapy, per phase 3 data.

Reducing ICI dose frequency in cancer patients led to more deaths, prompting early trial termination and highlighting risks of less frequent dosing.

Trastuzumab rezetecan significantly improves progression-free survival in HER2-low advanced breast cancer, regardless of ...